Press Releases

Date	Title	File/s
Jun 25, 2026	Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Jun 24, 2026	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Jun 24, 2026	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Jun 22, 2026	Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Jun 05, 2026	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2026	Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 01, 2026	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apr 29, 2026	Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Apr 27, 2026	Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Apr 03, 2026	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)